Aktis Oncology, Inc. (AKTS)

27.05USD +1.50% (+0.40)

Over 1M: +12.1%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

24 25 26 27
7 Aug 12 Aug 17 Aug 20 Aug 25 Aug 28 Aug 2 Sep

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q1 '25 — Revenue: 1.4M Q1 '25 — Free Cash Flow: -19.4M Q2 '25 — Revenue: 1.6M Q2 '25 — Free Cash Flow: -17.7M Q1 '26 — Revenue: 3.2M Q1 '26 — Free Cash Flow: -26.1M Q2 '26 — Revenue: 3.4M Q2 '26 — Free Cash Flow: -21.8M -24M -18M -12M -6M 0 6M
Q1 '25 Q2 '25 Q1 '26 Q2 '26
Revenue Gross Profit Free Cash Flow

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 94.4%
OE margin -819.7%
Oper. margin -780.6%
Accruals 0.42%
Asset turnover 0.012×
EBITDA margin -757.4%
FCF margin -725.2%
OCF margin -678.1%
Profit margin -642.4%
ROA -7.6%
ROCE -9.8%
ROE -8.8%
Gross margin —
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
P/B 3.0×
P/C 17.5×
FCF yield -3.3%
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
Fwd P/E —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

0.5
RPO / sales —
RPO growth —
Segment HHI —

0 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.3
Current ratio 35.5×
ND/EBITDA 0.061
Cash runway 1.7 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 16.3×
Cash / Debt —
F-score —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

10.0
Sales/sh Y/Y +116.9%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —
Sales Q/Q —
Shares change —

1 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.